Skip to main content
. 2021 Dec 15;11(12):6107–6118.

Figure 1.

Figure 1

Patient inclusion flowchart. A total of 774 patients received DEB-TACE+LEN or DEB-TACE+SOR as an initial treatment for advanced HCC between 2017 and 2020. Of these, 54 patients in the DEB-TACE+LEN group and 199 in the DEB-TACE+SOR group met the eligibility criteria of this study. After propensity score matching, safety and efficacy was compared between 50 patients in the DEB-TACE+LEN group and 100 in the DEB-TACE+SOR group.